Cystic fibrosis: NHS England strikes deal to offer triple combination treatment

被引：2
|
作者：
Iacobucci, Gareth
机构：
来源：
BMJ-BRITISH MEDICAL JOURNAL | 2020年 / 370卷
关键词：
D O I：
10.1136/bmj.m2643
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Triple combination CFTR modulator therapy reduces the need for endoscopic sinus surgery in adult patients with cystic fibrosis
    Tagliati, Corrado
    Lanni, Giuseppe
    Battista, Davide
    Pantano, Stefano
    Ripani, Pietro
    [J]. CLINICAL OTOLARYNGOLOGY, 2024, 49 (02) : 243 - 246
  • [32] Real-World Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Pediatric Patients with Cystic Fibrosis
    Nazzari, E.
    Russo, M.
    Faelli, N.
    Rosazza, C.
    Bricchi, S.
    Rizza, C.
    Alicandro, G.
    Dacco, V
    [J]. PEDIATRIC PULMONOLOGY, 2023, 58 : S115 - S115
  • [33] Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
    Bacalhau, Mafalda
    Camargo, Mariana
    Magalhaes-Ghiotto, Grace A. V.
    Drumond, Sybelle
    Castelletti, Carlos Henrique M.
    Lopes-Pacheco, Miqueias
    [J]. PHARMACEUTICALS, 2023, 16 (03)
  • [34] State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and Triple-Combination Therapy
    Meoli, Aniello
    Fainardi, Valentina
    Deolmi, Michela
    Chiopris, Giulia
    Marinelli, Francesca
    Caminiti, Caterina
    Esposito, Susanna
    Pisi, Giovanna
    [J]. PHARMACEUTICALS, 2021, 14 (09)
  • [35] Gallbladder sludge and microlithiasis disappearance in a cystic fibrosis patient 1 year after triple combination therapy initiation
    Tagliati, Corrado
    Veri, Daniele
    Pietra, Andrea
    Lanni, Giuseppe
    Battista, Davide
    Fogante, Marco
    Argalia, Giulio
    Lanza, Cecilia
    Pantano, Stefano
    Collini, Francesca
    Di Sabatino, Maria
    Ripani, Pietro
    [J]. CLINICAL CASE REPORTS, 2024, 12 (10):
  • [36] COST EFFECTIVENESS OF IVACAFTOR AND LUMACAFTOR COMBINATION FOR THE TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS IN THE UNITED STATES
    Sharma, D.
    Xing, S.
    Hung, Y.
    Caskey, R. N.
    Dowell, M. L.
    Touchette, D. R.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A431 - A432
  • [37] CFTR modulators and ganglioside GM1: a new combination for the treatment of cystic fibrosis
    Dobi, D.
    Loberto, N.
    Bassi, R.
    Mauri, L.
    Dechecchi, M. C.
    Tedesco, E.
    Olioso, D.
    Cabrini, G.
    Lippi, G.
    Pedemonte, N.
    Tamanini, A.
    Aureli, M.
    [J]. FEBS OPEN BIO, 2022, 12 : 270 - 271
  • [38] NOVEL INHALED TREATMENT FOR CYSTIC FIBROSIS, MANUFACTURED USING A COMBINATION PROCESS OF SPRAY DRYING AND MICRONISATION
    Naylor, Andrew
    O'Neil, Deborah
    Fraser-Pitt, Douglas
    Mason, Laura
    Johnson, Richard
    [J]. JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2020, 33 (02) : A12 - A13
  • [39] Cystic Fibrosis-Asthma Overlap Syndrome. Combination of Cystic Fibrosis Transmembrane Conductance Regulator Modulators and Type 2 Targeted Biologic Treatment for Asthma
    Jimenez-Gomez, Miguel
    Campos, Rocio Magdalena Diaz
    Caceres, Layla Diab
    [J]. ARCHIVOS DE BRONCONEUMOLOGIA, 2023, 59 (08): : 512 - 513
  • [40] Description of the variations in airway colonization in patients with cystic fibrosis in treatment with the combination of Ivacaftor, Tezacaftor and Elexacaftor (ITE)
    Benito Paton, Jonathan
    Iniesta Gonzalez, Sergio
    Lopez Pavia, Claudia
    Perez Sanz, Teresa
    Gonzalez Alvarez, Lucia
    Arcos Machancoses, Jose Vicente
    Crehua Gaudiza, Elena
    Castillo Corullon, Silvia
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 62
12345